These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11921523)

  • 1. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
    Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
    Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
    Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
    Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
    Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
    J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer.
    Goetz M; Steen PD
    Am J Gastroenterol; 1997 Aug; 92(8):1390-1. PubMed ID: 9260821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
    Nouts A; Lévy P; Voitot H; Bernades P
    Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of elevated levels of serum CA 19-9.
    Pavai S; Yap SF
    Med J Malaysia; 2003 Dec; 58(5):667-72. PubMed ID: 15190651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
    Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
    Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
    Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.